Gynecologic Oncology Group   Report issue

Foundation Phase 1 Phase 2 Phase 3
Founded: Philadelphia PA United States (1970)

Organization Overview

First Clinical Trial
1992
NCT00002493
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2100

Timeline

NOW
  • Now

Alternative names

GOG | Gynecologic Oncology Group | Gynecologic Oncology Group (GOG) | The Gynecologic Oncology Group (GOG) Foundation Inc

Active Ingredients

Drugs in Phase 3 Trials (43)

acetylcarnitine (1 trial)

amifostine (ethyol) (2 trials)

autologous hematopoietic stem cells (2 trials)

bevacizumab (avastin) (9 trials)

bone autograft (1 trial)

carboplatin (paraplatin) (35 trials)

cisplatin (platinol) (51 trials)

conjugated equine estrogens (Premarin) (1 trial)

cyclophosphamide (cytoxan) (4 trials)

dactinomycin (cosmegen) (3 trials)

docetaxel (taxotere) (12 trials)

dostarlimab (Jemperli) (2 trials)

doxorubicin (Doxil) (22 trials)

durvalumab (imfinzi) (2 trials)

epoetin (Epogen) (1 trial)

Filgrastim (neupogen) (8 trials)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (16 trials)

HPV16-E7-T512 (1 trial)

human fibrin (Tisseel) (1 trial)

ifosfamide (ifex) (3 trials)

leucovorin (1 trial)

megestrol (megace) (2 trials)

mirvetuximab soravtansine (Elahere) (2 trials)

mitoxantrone (novantrone) (1 trial)

naltrexone (revia) (2 trials)

niraparib (zejula) (2 trials)

olaparib (lynparza) (3 trials)

oregovomab (2 trials)

paclitaxel (taxol) (61 trials)

pembrolizumab (keytruda) (3 trials)

polyvalent antigen-klh conjugate vaccine (2 trials)

relacorilant (1 trial)

saponin (1 trial)

sargramostim (leukine) (15 trials)

sitagliptin (januvia) (1 trial)

tamoxifen (nolvadex) (3 trials)

thalidomide (Thalomid) (4 trials)

tirapazamine (2 trials)

topotecan (hycamtin) (16 trials)

veliparib (1 trial)

vincristine (oncovin) (1 trial)

vinorelbine (navelbine) (2 trials)

Drugs in Phase 2 Trials (66)

abemaciclib (verzenio) (1 trial)

adagloxad simolenin (1 trial)

aflibercept (zaltrap) (1 trial)

alvocidib (1 trial)

aminocamptothecin (1 trial)

attenuated live listeria encoding hpv 16 e7 vaccine (1 trial)

bacille calmette-guerin (1 trial)

belinostat (beleodaq) (1 trial)

bleomycin (blenoxane) (1 trial)

bortezomib (velcade) (1 trial)

brivanib alaninate (2 trials)

cabozantinib (cometriq) (1 trial)

capecitabine (xeloda) (3 trials)

celecoxib (celebrex) (2 trials)

cetuximab (erbitux) (4 trials)

dacarbazine (dtic-dome) (1 trial)

dalantercept (2 trials)

danazol (danocrine) (1 trial)

dasatinib (sprycel) (1 trial)

defactinib (1 trial)

dinitrophenol (1 trial)

Elesclomol (1 trial)

enzastaurin (2 trials)

epacadostat (1 trial)

erlotinib (tarceva) (1 trial)

etoposide (vepesid) (4 trials)

everolimus (zortress) (2 trials)

fulvestrant (faslodex) (1 trial)

gefitinib (iressa) (2 trials)

imatinib (gleevec) (2 trials)

iniparib (1 trial)

ixabepilone (ixempra) (3 trials)

karenitecin (1 trial)

lapatinib (tykerb) (2 trials)

letrozole (femara) (2 trials)

medroxyprogesterone (provera) (3 trials)

mgi-114 (2 trials)

mifepristone (mifeprex) (1 trial)

mitomycin (mutamycin) (2 trials)

motesanib (1 trial)

motolimod (2 trials)

nintedanib (ofev) (1 trial)

norgestrel (Ovral) (1 trial)

oxaliplatin (eloxatin) (3 trials)

pazopanib (votrient) (1 trial)

peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1 (1 trial)

pemetrexed (alimta) (9 trials)

pemigatinib (Pemazyre) (1 trial)

retifanlimab (1 trial)

rilotumumab (1 trial)

romiplostim (nplate) (1 trial)

rubitecan (1 trial)

selumetinib (Koselugo) (1 trial)

sorafenib (nexavar) (1 trial)

sunitinib (sutent) (1 trial)

temsirolimus (torisel) (2 trials)

tisotumab vedotin (TIVDAK) (2 trials)

trabectedin (yondelis) (2 trials)

trastuzumab (herceptin) (1 trial)

trebananib (1 trial)

triapine (1 trial)

urea (2 trials)

urokinase-derived peptide a6 (1 trial)

Verpasep (1 trial)

vorinostat (zolinza) (1 trial)

vs-6766 (1 trial)

Drugs in Phase 1 Trials (1)

egen-001 (1 trial)

Drugs in Other Trials (7)

aprepitant (Emend) (1 trial)

ef5 (1 trial)

granisetron (kytril) (1 trial)

isosulfan blue (lymphazurin) (1 trial)

methylene blue (proveblue) (1 trial)

n-(4-hydroxyphenyl)all-trans retinamide (1 trial)

technetium tc-99m sulfur colloid kit (Tesuloid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Adenocarcinoma, Clear Cell (Phase 3)

Adenocarcinoma, Mucinous (Phase 3)

Adenomyoepithelioma (Phase 2)

Anemia (Phase 3)

Brenner Tumor (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Adenosquamous (Phase 3)

Carcinoma, Endometrioid (Phase 3)

Carcinoma in Situ (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Carcinoma, Small Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 3)

Carcinosarcoma (Phase 3)

Cervical Intraepithelial Neoplasia (Phase 2)

Choriocarcinoma (Phase 3)

Communicable Diseases (Phase 1)

Cystadenocarcinoma (Phase 3)

Cystadenocarcinoma, Mucinous (Phase 3)

Cystadenocarcinoma, Serous (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Endometrial Hyperplasia (Phase 2)

Endometrial Neoplasms (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Fatigue (Phase 3)

Genital Neoplasms, Female (Phase 2)

Gestational Trophoblastic Disease (Phase 3)

Granulosa Cell Tumor (Phase 2)

Hereditary Breast and Ovarian Cancer Syndrome (Phase 2)

Hydatidiform Mole (Phase 3)

Hyperplasia (Phase 2)

Infections (Phase 1)

Infertility (Phase 3)

Leiomyosarcoma (Phase 3)

Leydig Cell Tumor (Phase 2)

Lymphedema (Phase 3)

Mixed Tumor, Mullerian (Phase 3)

Neoplasms (Phase 3)

Neoplasms by Site (Phase 2)

Neurotoxicity Syndromes (Phase 3)

Neutropenia (Phase 1)

Osteoporosis (Phase 2)

Ovarian Neoplasms (Phase 3)

Papilloma (Phase 2)

Papillomavirus Infections (Phase 2)

Peripheral Nervous System Diseases (Phase 3)

Peritoneal Neoplasms (Phase 3)

Postoperative Complications (Phase 3)

Sarcoma (Phase 3)

Sarcoma, Endometrial Stromal (Phase 2)

Sertoli-Leydig Cell Tumor (Phase 2)

Sex Cord-Gonadal Stromal Tumors (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Trophoblastic Neoplasms (Phase 3)

Urogenital Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 3)

Uterine Neoplasms (Phase 2)

Vaginal Neoplasms (Phase 2)

Virus Diseases (Phase 2)

Vulvar Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 215
  • # of Trial APIs: 117